Analyst Price Target is $23.00
▲ +209.56% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Theseus Pharmaceuticals in the last 3 months. The average price target is $23.00, with a high forecast of $24.00 and a low forecast of $22.00. The average price target represents a 209.56% upside from the last price of $7.43.
Current Consensus is
The current consensus among 4 contributing investment analysts is to buy stock in Theseus Pharmaceuticals.
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.